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ABSTRACT
THE CATALYTIC UREASE SUBUNIT UREC IS CRITICAL FOR
BIFIDOBACTERIUM LONGUM UREA UTILIZATION
SEPTEMBER 2019
YANG LYU
B.S., CHINA AGRICULTURAL UNIVERSITY, CHINA
M.S., CHINA AGRICULTURAL UNIVERSITY, CHINA
PH.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA

Directed by: Professor David A. Sela

In the first study, we investigated the utilization of a human milk nitrogen source,
urea, by Bifidobacterium. Urea accounts for ~15% in human milk, which is an abundant
non-protein nitrogen (NPN). Some bifidobacteria are found to harbor urease gene
clusters that potentially enable their hydrolysis of the human milk urea. However, the
underlying mechanisms are still unclear. To incisively link the urease gene cluster with
bifidobacterial urea utilization, chemical mutagenesis (i.e. ethyl methanesulfonate) was
performed on the urease-positive Bifidobacterium longum subsp. suis UMA399.
Mutants were selected on differential media and genetic lesions were identified using
whole genome sequencing. A mutant that did not exhibit urease activity, or utilize urea
as a primary nitrogen source, was selected for further characterization. We found that
a single-point mutation was located on the urease catalytic subunit ureC gene to prompt
a substitution at residue 343 from glutamic acid to lysine (E343K). Recombinantly
expressed and purified mutant UreC exhibits the loss of urease function. The mutation
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was complemented by expressing the wild-type UreC in the mutated strain. The
restoration of urease activity and urea utilization approached levels exhibited by the
wild-type strain. Thus, UreC is essential for the bifidobacterial urea utilization
phenotype.
In the ongoing research, we are exploring the ability of Bifidobacterium to
utilize cysteine, a sulfur-containing proteinogenic amino acid. Previous studies have
shown most Bifidobacterium cannot grow without cysteine (cysteine auxotrophic). It
will be interesting to clarify why bifidobacteria cannot synthesize cysteine and how
they assimilate cysteine from the gut environment as a necessity for propagation. Thus,
we first evaluated bifidobacterial strains on their ability to grow on different sole
nitrogen sources as well as sulfur sources. We found that only B. boum LMG10736 was
able to grow in methionine as a sole nitrogen source, the rest of the strains are all
cysteine auxotroph. However, B. boum LMG10736 was not able to utilize sulfate and
sulfide for its growth. We therefore proposed that the methionine degradation pathway
may be silenced under the transcriptional or translational regulations.
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CHAPTER 1
INTRODUCTION

The human gut microbiome is a complex system consists of diverse microbial
commensals, accounting for 1013-14 cells in the human gastrointestinal (GI) tract [1].
Over 1000 gut bacterial species have been characterized, from which most abundant
bacterial phyla are Bacteroides, Firmicutes, Proteobacteria and Actinobacteria [2].
Numerous studies have found that turbulence in human gut microbiota is associated
with many diseases such as diabetes [3], obesity [4], irritable bowel syndrome (IBS)
[5], autoimmune disease [6], allergy [7], cancer [8], even brain disease [9]. It is well
established that a healthy gut flora is responsible for overall health of the host [10]. The
human gut microbiota is known as a dynamic and evolutional system associated with
host diversity (e.g., age and genetic identity) and environmental factors (e.g., living
habits and geographic variations)
The colonization of intestinal bacteria begins in fetus and the infant gut
microbiota is established after birth. The early establishment of gut microbiota can be
affected by delivery mode (vaginal vs. caesarean section) [1]. The feeding mode,
including exclusively breastfeeding and formula feeding during the first 6 months
postpartum to 2 years of life will have profound effects on infant health and
development [11]. Certain human milk nutrients can selectively enrich beneficial
microbes in the infant microbiota, such as Bifidobacterium enriched by the human milk
oligosaccharides (HMOs). While HMOs maintain the predominance of certain infant
gut microbial cohorts, the access of nitrogen sources to the lower infant gut is unclear.
Compared to bovine milk, human milk contains less protein but more non-protein
nitrogen (NPN) [12]. The non-protein nitrogen compounds, including urea, uric acid,
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creatine, peptides, amino acids, nucleotides comprise ~25% of human milk nitrogen
[13]. The bioactive functions of these NPN compounds has not been well studied.
Our long-term goal is to investigate the interactions between human milk
molecules and the microbes that colonize the infant gut. We are seeking answers of
how human milk drives the establishment of the infant gut microbiome early in life and
how it contributes to infant health. The specific objective of this thesis work is to study
how the infant gut beneficial microbe, Bifidobacterium utilizes the human non-protein
nitrogen, Urea, via the function of their urease gene cluster. Our central hypothesis is
that human milk urea can be salvaged through bifidobacterial urease activity in the
infant gut and potentially provide a secondary nitrogen reservoir to the infant host. We
will test our hypothesis following the four specific aims:
Specific aim 1: Genomic analysis of the bifidobacterial urease gene cluster and
detecting urease activity in Bifidobacterium
Sequenced genomes in Bifidobacterium will be checked for presence or absence of the
urease genes. Multiple sequence alignment (MSA) will be performed on each gene of
urease gene cluster among variant (sub) species of Bifidobacterium, followed by
phylogenetic analyses. The configuration of a complete bifidobacterial urease gene
cluster will be visualized. A developed quantitative urease assay will be used to detect
urease activity in multiple bifidobacterial strains. The impact of substrate-Urea and
cofactor-Nickel on urease activity will also tested.
Specific aim 2: Developing a bifidobacterial urease mutant and the phenotypic
analysis of the mutant strain.
Bifidobacterium longum subsp. suis UMA399 will be treated with ethyl methane
sulfonate (EMS). Mutants generated from EMS mutagenesis and will be selected from
a developed differential agar, accompanied by phenotypic analyses. SNPs (Single
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Nucleotide Polymorphisms) and relative mutations will be identified by whole genome
sequencing and SNP-Calling. The mutant phenotype will be analyzed by both urease
assay and growth assay using urea as a primary nitrogen source. To study the protein
level deficiency of the mutant urease, the mutant urease will be overexpressed in E. coli
using the SUMO fusion system followed by biochemical characterization. To
complement the mutation, wild-type genes will be expressed on an E. coliBifidobacterium shuttle vector inside the mutant cells.
Specific aim 3: Developing genetic tools for Bifidobacterium longum subspecies
strains
An electro-transformation system that allows the transferring of multiple E. coliBifidobacterium shuttle vectors into Bifidobacterium longum subspecies strains will be
established via optimization of the electroporation method, including electroporation
wash buffers, intensity of electric pulse.
Specific aim 4: Exploring the cysteine auxotrophic behavior in Bifidobacterium and
initially predicting an underlying mechanism
Bifidobacterial strains from variant (sub) species will be tested on their growth ability
in different sole nitrogen sources, to check if they are cysteine auxotroph or prototroph.
To test if cysteine synthetic genes are silenced in the cysteine auxotrophic strains,
chemical mutagenesis will be performed on these strains and to select mutants that
turned to cysteine prototroph. Sequenced Bifidobacterial genomes will be checked for
presence or absence of the cysteine biosynthetic pathway genes to provide an initial
hypothesis for cysteine auxotrophic behavior in Bifidobacterium.
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CHAPTER 2
LITERATURE REVIEW
2.1 Introduction
Bifidobacterium, a major of human gut colonizer, have been widely reported for
their health benefits on human body such as improving immunity, reducing irritable
bowel syndrome (IBS), and lowering cholesterol [14-17]. Some bifidobacterial species
have been added to probiotic food or pharmaceuticals due to their beneficial effects.
Over the past decade, the knowledge on interactions of Bifidobacterium with variant
hosts and other gut members as well as their probiotic functions has been enhanced by
cutting-edge techniques (genome, transcriptome, proteome or metabolome analysis). It
is then important to deeply clarify the mechanisms behind those beneficial impacts. To
confirm that specific genes identified by omics data are essential for a pathway, gene
modification techniques such as knockout and gene overexpression are required.
However, compared to many other bacteria, gene modification systems have not been
established for the genus Bifidobacterium until recently. In this review, the barriers for
establishing gene modification systems as well as the current genetic tools available for
bifidobacteria will be comprehensively introduced.
2.2 Current barriers for developing genetic tools for Bifidobacterium
So far, several factors have been differentiated Bifidobacterium from other
bacteria regarding their low ability to take up and maintain outer DNAs. The first is the
thick cell wall of bifidobacteria. The multi-layers of peptidoglycan are proposed to
hinder the intake of exogenous DNA as the first barrier. The second factor is the
environmental stress such as oxygen that are toxic to bifidobacteria as they are general
anaerobes. The major factor that impede the developing of genetic tools for
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Bifidobacterium is the intracellular restriction/modification (R-M) systems. The R-M
system is a widely distributed protective mechanisms in prokaryotes against invading
DNAs such as phages. It comprises of a restriction endonuclease (REase) and cognate
methyltransferase (MTase) [18, 19] and can be classified into four groups (type I, II, III
and IV) [20]. In a type II R-M system, the bifidobacteria self-DNA is protected by
MTase methylation that modifies cytosyl or adenosyl residues within the DNA [21, 22].
These DNA loci is also recognized by the corresponding REase, but due to methylation,
REase will not cut self-DNA. In contrast, outer DNAs without methylation will be
recognized and cut by REase, which explains why exogenous DNA such as plasmids
are not stable in bifidobacteria. The distribution of the four R-M systems in
bifidobacteria is pretty strain-dependent and can be analyzed by REBASE
(http://rebase.neb.com/rebase) with known genome sequence [23]. Bifidobacterial
strains with more R-M systems are potentially more difficult to take up exogenous
DNAs compared to those with less R-M systems.
2.3 Transformation
Transformation is the process when competent bacteria are able to take up
foreign DNA into their cells. For bifidobacteria, electro-transformation or
electroporation is the most used method. During electroporation, an electric pulse is
applied and will create pores on the cell membrane. Negatively charged DNA like
plasmids or vectors get into the cells accordingly. The transformation of designed
vectors for overexpression or mutagenesis of specific genes are fundamental and
essential to study the beneficial effects of bifidobacteria. However, the application of
transformation is limited to various bifidobacterial species or strains. A major cause is
the presence of R-M systems which degrades foreign DNA imported into the cells. So
far, there has been many reports on certain bifidobacterial strains transformed with
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different E. coli- Bifidobacterium shuttle vectors [24-29]. Most shuttle vectors are
created by adding the E. coli replicons and antibiotic resistant markers to the backbone
of a bifidobacterial-originated plasmid which has been reviewed by Sun et. al [30].
Current transformation methodology for bifidobacteria has been advanced based on
previous studies during the past decades reviewed by Gulielmetti et. al [31]. Right now,
the conditions for making competent cells tends to be similar among various species.
Key experimental conditions include a prerequisite anaerobic environment, high
concentrations of sugars (sucrose, raffinose, fructo-oligosaccharides etc.) added into
the growth medium [24, 26, 29, 32], the using of mid-logarithmic-phase cells (OD600
nm

= 0.4 - 0.6) as well as a washing buffer containing high-amount sucrose (0.5 M), and

a 30 min preincubation before the electric pulse (25 µF, 200 W, 2.2 kV) are widely used
in most recent studies on bifidobacteria. In a recent study that transformed pBES2 into
B. bifidum, the use of 0.2 M NaCl as the cell wall weakening agent resulted in a 20-fold
increase in the efficiency [33]. Still, for unreported bifidobacterial species, an
optimization on the methodology is strongly recommended as strain/species-variance
is quite normal [31], The optimization includes conditions for making competent cell,
the amount of plasmid DNA used, as well as the electric pulse intensity. The median
transformation efficiency is 103 CFU per µg plasmid DNA by electroporation [34]. For
targeted mutagenesis using the vector for homologous recombination, the efficiency is
suggested to be above 105 CFU per µg plasmid DNA. Besides optimized transformation
conditions, plasmid artificial modification (PAM) on the vectors by the host
bifidobacterial methyltransferase genes has been found to improve their stability
against the R-M systems [27, 28, 35, 36] (Figure 1). In this strategy, the plasmid vectors
are propagated inside an E. coli expressing the methyltransferase from the target
bifidobacterial strain before introduced to the bifidobacterial cells. As vectors are
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modified, they are less recognized by the nuclease from the R-M systems and are more
stable inside the cell. In recent years, the use of single-molecule real-time (SMRT)
DNA sequencing enables a more accurate and comprehensive analysis on all the
recognition sequences of methyltransferases and the methylation site. This will further
facilitate the application of the PAM method and more likely increase the efficiency of
electro-transformation of interested Bifidobacterium in the future.
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Figure 1 The Plasmid Artificial Modification (PAM) strategy applied in
Bifidobacterium.
(1) Introduction of a PAM vector that expresses methylase from the target
bifidobacterial strain. (2) Introduction of the E. coli-Bifidobacterium shuttle vector into
the PAM host. (3) The shuttle vector is modified by methylase on the recognition sites.
(4) Extraction of the shuttle vectors from the PAM host. (5) Electro-transformation of
the shuttle vector into the target bifidobacterial cells. (6) The methylated shuttle vector
is protected from the nuclease cleavage and can propagates in the cells.
2.4 Heterologous gene expression in Bifidobacterium
So far, heterologous gene expression has been used for identifying the gene
functions of bifidobacteria, as well as using bifidobacteria as the carriers for expressing
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useful enzymes. Currently, antigen or prodrug-converting molecules have been
expressed in Bifidobacterium in order to use them as a live vaccine or for cancer therapy.
Thus, it is very important to establish a sophisticated heterologous gene expression
system for various experimental purposes. The major factors to consider for gene
expression modulation in bifidobacteria are promoter and the ribosome-binding-site
(RBS).
The promoter initiates the transcription of a gene by recruiting the RNA
polymerase and controls the gene expression. In bacteria, promoters are consisted by a
region from -35 sequence to a -10-sequence upstream transcription start site of the gene.
Promoter activity is a critical factor for heterologous gene expression, the low or high
activity of the chosen promoter is dependent on the purpose of the study. The
overexpression of an exogenous gene might be toxic to the host cells; while a strict
inducible promoter enables the control of its expressed genes. The activity of promoters
in bifidobacteria has been analyzed in many studies reviewed by [30], via the promoterreporter assay [37]. The reporter genes so far used include the green fluorescent protein,
beta-glucuronidase (gusA), and luciferase. In particularly, the luciferase reporter system
is applicable to measure the promoter activity in vivo [38]. The constitutive promoters
gap (Pgap) and hup (Phug) has shown high activities in bifidobacteria [39]. Inducible
promoters, such as the arabinose inducible promoter PBAD [40] and a bile-induced
promoter PBile [41] has been used for controlled gene expression in bifidobacteria. For
bifidobacteria that are not able to utilize arabinose, PBAD will not be suitable.
The translational regulation is also an important factor to consider when
performing heterologous gene expression, in this case ribosome-binding-site (RBS).
RBS is usually optimized for translation initiation efficiency of a target gene. In
Bifidobacterium, the length of the RBS as well as its distance to the start codon will
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both influence the gene expression [42]. An optimal RBS has been identified B. longum
105-A, with the sequence (5’-AAGGAG-3’) [43], which is quite different from the RBS
conserved in E. coli (5’-AAGGAG-3’). The optimal distance to the start codon is
suggested to be 5 bp. So far, limited knowledge is known about the translational
regulation in Bifidobacterium. Future efforts are significant to elucidate both the
transcriptional and translational impact on the gene expression in Bifidobacterium that
can support their future application as gene-manipulated drug carrier in
pharmaceuticals.
2.5 Mutagenesis systems in Bifidobacterium
2.5.1 Targeted mutagenesis
The most direct way to study gene function is by reverse genetics. Reverse
genetic tools include directed gene knockout, gene silencing, and transgene interference.
In many bacteria, targeted gene knockout via homologous recombination has been
frequently used [44]. In bifidobacteria, the currently utilized targeted gene mutagenesis
system is homologous recombination [44]. During homologous recombination,
designed non-replicating plasmids with two homology arms on each side flanking the
desired mutation or insertion. Target gene is split during single-crossover or doublecrossover of the plasmid internal region and the chromosomal target gene. Even though
this technique is quite established in other gram-positive bacteria such as Lactobacillus,
it is very difficult to perform in Bifidobacterium until currently. The reason is still
attributed to the R-M systems that prevent the introduction of the vectors for
homologous recombination [45]. To date, only a few targeted gene knockout tools are
available for certain bifidobacterial species including B. longum NCC2705 and B. breve
UCC2003 by combining the plasmid artificial modifications (PAM) with a homologous
recombination system as mentioned previously [45, 46]. The shuttle vector, in this case

10

designed for homologous recombination is propagated inside the E. coli PAM host
expressing the methylase from Bifidobacterium of interest. Vectors are therefore
modified by methylation before entering bifidobacterial cells for recombination. As
modified shuttle vectors is to some extent protected from the endonuclease of the R-M
systems, it is more stable. Therefore, there will be more opportunities to have the vector
cross-over or recombination with the target gene loci on the chromosome. However,
the PAM-based methods are strongly strain-dependent and limited for most
bifidobacteria. So far, this technique has only been successful in B. longum NCC2705
[46, 47], B. longum 105-A [46, 48], B. longum 35624 [36], B. longum NCIMB8809
[49], B. lactis NCC2818 [50], B. lactis DSM10140 [51], B. breve UCC2003 [16, 5256], B. breve BR-A29 [57], B. breve JCM7017 [58, 59] and B. breve NCFB2258 [52].
As for homologous recombination by using Bifidobacterium strains, a relatively high
transformation efficiency of over 104 CFU per µg DNA is demonstrated. Thus, for
strains with low transformation efficiency, this system is not applicable. Future efforts
toward the development of broad-range targeted gene mutagenesis techniques are still
of great demand.
2.5.2 Random mutagenesis
Forward genetics is another way to identify sequence variations responsible for
a given phenotype of an organism. Different from reverse genetics that causes known
sequence changes, this approach identifies the mutant phenotype from random
mutagenesis or natural spontaneous mutation [60]. The mutant is selected with the
phenotype of interest, followed by the mapping of gene mutations throughout the
chromosomes. Random mutagenesis can be introduced by chemical mutagens or by
UV [61]. One of the frequently used chemical mutagen is ethyl methane sulfonate
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(EMS). EMS can cause base-pair transitions from C/G-to-A/T on the target genome,
resulting in random loss of functions in the mutants [62]. As mentioned previously,
tools for targeted mutagenesis for Bifidobacterium are very limited. The development
of reverse genetic tools is time-consuming as well. However, chemical mutagenesis
provides a convenient way to generate mutants from Bifidobacterium. EMS has been
extensively used in various organisms, including prokaryotes and eukaryotes.
Particularly, it has been applied to B. breve and B. longum strains to select mutants [63,
64].
Besides chemical mutagenesis, a Tn5-based transposon mutagenesis system has
been applied to Bifidobacterium breve UCC2003 and Bifidobacterium breve
NCFB2258 [65]. A transposon is a DNA sequence that can are able to move within a
genome, sometimes creating or reversing mutations on the bacterial genome [66].
Using transposon mutagenesis, a mutant library with genome-wide transposoninsertion mutations can be created followed by phenotypic screenings for desired
phenotype [67]. However, this experiment also needs plasmids transferred into the
bifidobacterial strain, which requires transformation efficiency. Therefore, the
application of chemical mutagenesis maybe a better tool for creating random mutations
in Bifidobacterium.
2.6 Future Perspectives
In recent years, CRISPR-Cas9 has enabled targeted gene editing in variant
species [68]. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) are
short sequences identified in bacterial genomes as results of viral DNA invasion.
Transcription of the CRISPR-array yields RNA fragments called CRISPR-RNA
(crRNA). The crRNA directs the Cas9 nuclease to the target DNA (also called Spacer)
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adjacent to a Protospacer-Adjacent Motif (PAM) (~4-5 base pairs downstream). The
Cas9-mediated DNA cleavage results in a double-strand break (DSB) within the target
DNA (~3-4 nucleotides upstream of the PAM sequence), intriguing DSB repair. During
this process, mismatches or mutations on the target DNA are artificially introduced.
The Cas9-induced DSB may be lethal to the bacteria [69]. However, assisted by DNA
recombineering, CRISPR-Cas9 has been used as a counter-selection tool in generating
mutants from Lactobacillus reuteri [70]. In this particular method, a single-stranded
DNA (ssDNA) homologous to the target gene and a vector expressing the ssDNAbinding protein Beta, are introduced into the bacteria. Once Beta is expressed by the
vector, it will combine the ssDNA and protect it from intracellular nuclease degradation.
Due to the homology to the target gene, this ssDNA can be recognized by DNA
polymerases as a template for DNA replication and incorporated into the synthesis of
lagging strand. Mismatches or mutations are introduced at the target gene once the
ssDNA is extended into a new daughter strand [71]. Mutants harboring the pointmutations from DNA recombineering will not be recognized by Cas9 and can survive
during the selection. The wild-type cells with no DNA recombineering still have PAM
sequence and will be cut by Cas9. The CRISPR-Cas9-assisted recombineering applied
in Lactobacillus reduces the labor for selecting mutants and is a promising technique
to apply to Bifidobacterium. However, the use of multiple shuttle vectors in this method
might be a challenge for Bifidobacterium, as there have been no trials on transferring
more than one shuttle vector into the bifidobacterial cells so far. Compared to
Lactobacillus, Bifidobacterium are proposed to be more recalcitrant to genetic
manipulations [72] . To our knowledge, there has been no report on using CRISPRCas9 to generate mutants from the genus of Bifidobacterium. The development of
methodologies such as CRISPR-Cas9 to facilitate the genetic accessibility will be
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promising and significant for functional genomic analyses of the genus of
Bifidobacterium.
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3.1 Introduction
It has been widely reported that the infant microbiota plays a vital role during
infant early development before weaning. Certain components from breast milk
selectively enrich beneficial microbes in the infant microbiota and shape its
configuration. Human milk oligosaccharides (HMOs), a category of soluble but nondigestible carbohydrates to the neonates, can enhance the growth of bifidobacteria [7375]. While HMOs maintain the predominance of certain infant gut microbial cohorts,
the bioavailability of consumed nitrogen sources in the lower infant gut is unclear.
Compared to bovine milk, human milk contains less protein but more non-protein
nitrogen (NPN) [12]. Interestingly, urea is one of the major forms and its proportion
amounts to ~15% of the total nitrogen in human milk [76]. The discovery of urea
metabolism genes in Bifidobacterium longum subsp. infantis ATCC15697 may be
correlated with human milk nitrogen in the nursing infant gut microbiome [77]. The
urea metabolism proteins include a transport system (urtA, urtB, urtC, urtD, urtE),
ureAB, urease subunit gamma/beta, ureC, urease subunit alpha, and urease accessory
proteins (ureE, ureF, ureG, ureD), which are highly specific to the subspecies of B.
infantis [78]. Urease (EC 3.5.1.5), which degrades urea into ammonia and carbon
dioxide, is widely distributed in bacteria including Helicobacter pylori, Staphylococcus,
Lactobacillus, and Proteus. Specifically, in H. pylori, urease has been found to facilitate
colonization of the stomach by elevating pH [79]. As for B. infantis, the function of this
urease gene island is still under investigation. Although the identification of the urease
gene island has been relatively recent, the production of urease by bifidobacteria was
analyzed by Matteuzzi et al. in the species B. suis in 1973. They found 74% of the
tested B. suis strains possess this enzyme [80]. In addition, Suzuki et al. studied the
urease activity of bacteria isolated from human infant feces and found that all B. infantis
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are urease positive [81]. Later on, Crociani et al. surveyed 414 bifidobacterial strains
representing 21 species, and found that all B. infantis and some B. breve hydrolyzed
urea, while B. suis was the strongest ureolytic species [82]. These early studies
indicated that urease activity is dispersed in various species and subspecies of the genus
Bifidobacterium. However, the driving force for retention of urease genes within
Bifidobacterium genome is still poorly understood.
Given that Bifidobacterium correlates tightly with the infant host regarding
human milk nutrients, it is natural to hypothesize a potential utilization of human milk
urea by these microbes. In 1969, researchers tracking labelled ammonium-15N in child
malnutrition indicated that labelled ammonium may be incorporated into blood cells
and plasma protein, providing essential nitrogen in the malnourished state [83]. In 1992,
Heine et al. used 15N-labeled B. breve to track whether bifidobacterial nitrogen can be
absorbed by the infant. Results showed that 90% of 15N-labeled B. breve nitrogen was
absorbed and 70% was retained in the infant protein pool, indicating a nutrient flow
from the microbes to the host [84]. Fuller et al. brought forward the concept of urea
nitrogen salvaging (UNS), a process of bacteria-induced colonic urea recycling in
which enterocytes can actively transport urea into the intestinal lumen for bacterial
usage [85]. Millard et al. used 15N-labeled urea to track ammonia hydrolyzed from
infant bacteria and observed an increased supply of lysine and other indispensable
amino acids to the infant host, supporting the hypothesized model of urea nitrogen
salvaging by the infant gut microbiota [86].
The mechanism of bifidobacterial urease activity and its interactions with
human milk urea remains elusive. To understand bifidobacterial urea utilization,
molecular tools for genetic manipulation are necessary for investigating urease gene
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activity in sufficient detail. While restriction-modification systems (R-M systems) are
still one of the major barriers to gene modification [27], targeted mutagenesis has been
successful in few strains [27, 28]. Here, we developed a urease deficient mutant from a
urease-positive strain Bifidobacterium longum subsp. suis UMA399 via chemical
mutagenesis. This mutant model has allowed us to initially investigate the genetic basis
and functional characteristics of bifidobacterial urease in greater depth than previous
studies.
3.2 Material and Methods
3.2.1 Bacterial Strains and Culture Conditions
Bacterial strains in this study are listed in Supplemental Table A1. Single
colonies of bifidobacteria were grown overnight in De Man-Rogosa-Sharpe (MRS)
broth (Difco, USA) supplemented with 0.05% (wt/v) L-cysteine and incubated
overnight at 37˚C in a Coy anaerobic chamber (Coy Laboratory Products, MI).
Escherichia coli strains were grown in Luria-Bertani (LB) broth. For selecting E. coli,
LB was supplemented with 20 mg mL-1 chloramphenicol for pDOJHR, 34 mg mL-1 for
Rosetta (DE3) and 50 mg mL-1 kanamycin for pSMT3, respectively. For bifidobacteria,
the using of 5 µg mL-1 chloramphenicol in MRS media was previously determined by
a MIC (minimal inhibitory concentration) assay.
3.2.2 Mutant generation by Ethyl methane sulfonate (EMS)
Bifidobacterial cells from a 4 mL of overnight culture were spun down and
resuspended in 4.75 mL phosphate buffer [pH7.2]. A 250 µL of EMS (99%) was added
to reach a final concentration of 5% (v/v). The mixture was incubated at 37˚C for 30
min. Cells were pelleted again and washed 3 times with fresh MRS. Cells suspension
in 5 mL fresh MRS was diluted to 25% of the original concentration and grown
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overnight. Dilutions of 100 µL overnight mutagenized cultures were spread on a urease
differential agar optimized from Monnet et al. [87]. The urease differential agar was
made from GAM Broth (HI-Media, India) supplemented with 0.5% (wt/v) glucose,
0.001% bromothymol blue, and 4.5% (wt/v) urea. Plates were incubated anaerobically
at 37˚C for 5 days. Whitish colonies (as opposed to the urease-positive dark green
colonies) were selected and cultured for genomic DNA extraction and sequencing.
3.2.3 Genome Sequencing and SNP Analysis
Genomic DNA was extracted from 5 mL overnight cultures using the
MasterPure Gram-positive DNA purification kit (Epicentre [an Illumina Company],
Madison, WI). DNA quality and quantity were determined using a NanoDrop 2000
Spectrophotometer

and

a

Qubit

2.0

Fluorometer

(ThermoFisher,

USA),

respectively. Sequencing libraries were prepared using the Nextera XT 150-bp pairedend library preparation kit (Illumina, San Diego, CA). Whole-genome sequencing was
performed on the Illumina NextSeq platform using v2 reagents. Reads were assembled
de novo via SPAdes version 3.9.1 and the assemblies were improved using Pilon
version 1.22 (Bankevich, 2012; Walker, 2014). Both analyses were conducted using
the Massachusetts Green HighPerformance Computing Center (mghpcc.org). Gene
model predictions and annotations were performed using the Rapid Annotation using
Subsystem Technology (RAST) annotation service (Overbeek, 2013). Single
nucleotide polymorphisms (SNP) were detected in the annotated wild-type and mutant
genome using the PATRIC version 3.5.30 Variation Analysis Service (Wattam, 2016)
via the aligner (BWA-mem-strict) and the SNP caller (FreeBayes). The urease gene
cluster of B. suis UMA399 and B. infantis UMA272 was depicted by SimpleSynteny
version 1.4 [88].
3.2.4 Microplate Growth Assay
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The growth phenotype of cells was monitored in a 96-well plate. Cells from
overnight MRS broth culture were used to inoculated at 1% (v/v) complex nitrogen and
urea broth modified from a basal medium (v/v) (2% lactose, 0.2% potassium phosphate
dibasic anhydrous, 0.3% sodium acetate anhydrous, 0.02% magnesium sulfate
heptahydrate, 0.0038% manganese (II) sulfate monohydrate, 0.1% Tween 80, and
0.022% L-cysteine). For the complex nitrogen media, an extra 1% peptone, 0.8% yeast
extract, and 0.1% ammonia citrate were added to the basal medium. For the urea broth,
an extra 2% urea was added to the basal medium as a primary nitrogen source. Growth
in basal media was regarded as the negative control. The growth assay was conducted
at 37˚C for 4 days in a microplate spectrophotometer (BioTek, USA) placed within the
anaerobic chamber. Reads were performed with shaking at intervals of 5 min to detect
optical density at 600 nm. Each strain was measured in biological triplicate with three
technical repeats.
3.2.5 Determination of Urease Activity
The urea assay was optimized for bifidobacteria based on a modified phenolhypochlorite assay [89]. Cells were harvested from 2 - 5 mL overnight culture and
washed three times with pre-chilled 25 mM HEPES buffer [pH 7.0]. A 2 mL volume
of cell resuspension in 25 mM HEPES was transferred to the lysing matrix E tube (MP
Biomedicals, USA) and was subjected to a FastPrep-24TM 5G homogenizer (MP
Biomedicals, USA). The bead-beating was done at a speed of 3.5 m/s for 30 s, three
times, with a chilling period between each round. Tubes were centrifuged at 16,200 ´
g for 10 min and the supernatant was kept. The cell protein concentration was measured
by Pierce BCA protein Assay kit (ThermoFisher, USA) on a NanoDrop (ThermoFisher,
USA). For the urease assay, 20 μL of proper diluted lysates were incubated with 20 μL
of urea buffer (25 mM HEPES [pH 7.0] plus 300 mM urea) in 96-well plates at 37 ̊C
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for 30 min. Then 75 μL of phenol plus nitroprusside was added to terminate the
reactions, followed by an equal volume (75 μL) of alkaline hypochlorite. The mixture
was incubated at 37 ̊C for 30 min. The absorbance at 620 nm was measured using a
plate reader (SpectraMax i3x, Molecular Devices, USA). The amount of ammonia
generated was calculated from a standard curve (0 - 50 nmol) made with ammonium
chloride dissolved in 25 mM HEPES [pH 7.0]. Urease activity was defined as
nanomoles of ammonia produced per minute per milligram of protein [nmol NH3 min1

(mg protein-1)]. To avoid the influence of ammonia released from urease-independent

reactions, cell free lysates in each replicate were incubated with 25 mM HEPES [pH
7.0] and the values of ammonia produced from these reactions were subtracted. Urease
activity of each strain was calculated as means of biological triplicates with three
technical repeats.
3.2.6 The Construction of the UreC expression Vector
The expression vector pSMT3 was a generous gift from Prof. Stratton from the
University of Massachusetts Amherst. Genomic DNA from bifidobacteria was
extracted using the MasterPure Gram positive DNA purification kit (Epicentre
Biotechnologies). The ureC coding sequence (CDS) was amplified by primer PSM-F/R
with Q5 High-fidelity DNA polymerase, in which BamHI and XhoI sites were inserted.
The PCR products were purified using a QIAquick PCR purification kit (Qiagen).
Purified Amplicon and pSMTS were digested with BamHI and XhoI, then cleaned by
Zymoclean Gel DNA Recovery Kit (Zymo Research). Ligation was done with T4 DNA
ligase (NEB) at 16˚C overnight then chemically transferred into E. coli NEB 5-alpha
(NEB, USA). All reagents were used according to the manufacturer’s instructions. The
transformants were confirmed further by linearization with BamHI and XhoI before
being subjected to insert sequencing by Genewiz (Boston, USA). The pSMT3 vector
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with wild-type or mutant ureC was named pSMT-U, as shown in Figure A4 drawn by
SnapGene (from GSL Biotech; available at snapgene.com).
3.2.7 Purification of UreC and In Vitro Urease Activity
The vector pSMT-U was chemically transformed into E. coli Rosetta (DE3) for
protein overexpression. Single colonies were grown in 5 mL cultures (LB kana/cam)
overnight at 37˚C. Then, 1% (v/v) of this overnight culture was inoculated into 70 mL
LB (kana/cam) and grown until OD600

nm

reached 0.8 - 1.0. Isopropyl b-D-

thiogalactoside (IPTG) was added to the culture to a final concentration of 0.1 mM. The
mixture was incubated at 32˚C for 4 hours with shaking (250 rpm). Cells were harvested
by centrifugation and sonicated in 8 mL phosphate buffer (pH 7.4) via a Microson
Ultrasonic Cell Disruptor (Microson, USA) using six 10-second bursts at high intensity
with a 10-second cooling between each burst for 30 min. Cell suspensions were
centrifuged at 4,696 ´ g for 5 min to remove the cellular debris. Then, 8 mL of the
supernatant was purified using the HisPur Ni-NTA Spin Columns (ThermoFisher,
USA), washed with 25mM imidazole (phosphate buffer [pH 7.2]) twice, 60 mM
imidazole (phosphate buffer [pH 7.2]) once, and then was eluted three times by 250
mM imidazole (phosphate buffer [pH 7.2]) as the 6xHis-SUMO-UreC. Imidazole in the
protein suspension was removed by desalting through the Amicon Ultra-15 Centrifugal
Filter Unit (30kDa MWCO) (Millipore, USA) against the buffer (50 mM Tris-HCl, 150
mM NaCl, pH 8.0) at 4˚C. L at 4˚C overnight. To cleave the 6xHis-SUMO tag, the
protein mixture after desalting was incubated with SUMO protease in buffer (50 mM
Tris-HCl, 150 mM NaCl, pH 8.0) supplemented with 1mM DTT at 4˚C overnight. After
cleavage, DTT in the protein was removed by desalting against 10 mM imidazole in
PBS buffer (20 mM sodium phosphate, 300 mM NaCl, pH 7.4) in Amicon Ultra-15
Centrifugal Filter Unit (30kDa MWCO) and run through the NI-NTA column again to
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remove the 6xHis-SUMO tag. Purified UreC in the flow through was kept at 4˚C shortly
and immediately used for in vitro urease activity measurements. The in vitro urease
activity assay was based on a previous study [90]. Mutant cell free lysates were
prepared by bead-beating. The bead-beating was done at a speed of 3.5 m/s for 30 s,
three times, with a chilling period between each round. Tubes were centrifuged at
16,200 ´ g for 10 min and the supernatant was kept. The cell protein concentration was
measured by Pierce BCA protein Assay kit (ThermoFisher, USA) on a NanoDrop
(ThermoFisher, USA). A 12 µL (~20 µg) purified wild-type UreC or Mut UreC was
incubated with 12 µL mutant cell free lysates in 12 µL of 25 mM HEPES buffer. The
solution was incubated at 25˚C for 24 hours and then at 37˚C for 12 hours. To determine
the urease activity, 5 µL of the incubated solution was added to 245 µL of reaction
buffer (50 mM HEPES, 25 mM urea [pH 7.0]) and incubated for 30 min. Then, 375 μL
of phenol plus nitroprusside was added to terminate the reactions. An equal volume
(375 μL) of alkaline hypochlorite was then added and incubated at 37 ̊C for 30 min.
The amount of ammonia generated was calculated from a standard curve (0 - 5 nmol)
made with ammonium chloride dissolved in 25 mM HEPES [pH 7.0]. Urease activity
was defined as nanomoles of ammonia produced per minute per milligram of protein
[nmol NH3 min-1 (mg protein-1)].
3.2.8 Differential Scanning fluorimetry (DSF)
To compare the difference of nickel binding between the mutant and wild-type
UreC. A differential scanning fluorimetry of both proteins incubated in Ni2+ was
performed according to Niesen et al. [91]. Specifically, nickel chloride was dissolved
in 100% DMSO with a final concentration of 400 µM. Then, the 100% DMSO was
diluted into 10 mM HEPES [pH 7.0] in a ratio of 1:1000]. A 4.2 mL purified UreC in
10 mM HEPES [pH 7.0] solution was mixed with 5 x SYPRO Orange fluorescence dye
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(ThermoFisher, USA). Samples were added to a 96-well plate. In each well, 39 µL of
protein solution and 1 µL of Ni2+ were mixed, with a final Ni2+ concentration of 10 µM.
The plate was then covered a with foil seal (Agilent Technologies), centrifuged to avoid
bubbles. and measured on 7500 Fast Real-Time PCR System according to the settings
outlined in Niesen et al. Each group was measured in 6 technical replicates.
3.2.9 Construction of the UreC expression Shuttle Vector
DNA manipulations and molecular techniques were conducted as described
above. The E. coli-Bifidobacterium shuttle vector pDOJHR was a kind gift from Prof.
Sullivan [26]. The ~100 bp upstream and ~60 bp downstream regions flanking the ureC
coding sequence (CDS) were amplified by primer PD-F/R, in which EcoRI sites were
incorporated. For the construction of pDOJ-U, the amplicon and pDOJHR were
digested with EcoRI, ligated by T4 DNA ligase, and transferred to E. coli strain NEB
5-alpha (NEB, USA). The insert within the plasmid was sequenced by Eton Bioscience
(Boston, USA) to ensure that only the right DNA fragments had been introduced.
3.2.10 Electroporation and Plasmid Isolation from the Mutant
A 5% (v/v) overnight culture of the mutant strain was used to inoculate 40 mL
MRS (Difco, USA) supplemented with 0.05% L-cysteine and incubated at 37˚C until
an OD600 nm of 0.4-0.5 was reached. Cells were collected at 4,696 ´ g for 15 min at 4˚C,
then washed 3 times with 30 mL ice-cold electroporation buffer [10% (v/v) glycerol
and 0.5 M sucrose]. Cells were resuspended in 1 mL buffer in a microcentrifuge tube,
pelleted again, and resuspended in 1/250 (v/v) of the original culture. For each
transformation, 50 µL of the cell suspension and 400 ng of plasmid DNA were mixed
and incubated on ice for 30 min, then transferred to a pre-chilled 1 mm disposable
cuvette. A voltage electric pulse was delivered through a Gene Pulser (Bio-Rad) at 25
µF, 200 W and 2.2 kV. Cells were immediately resuspended with 950 µL of MRS
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(Difco, USA), transferred into a 15 mL falcon tube, and recovered anaerobically for 3
hours at 37˚C. After which, cells were diluted and plated on aluminum foil-wrapped
MRS plates supplemented with 5 µg mL-1 chloramphenicol and incubated
anaerobically at 37˚C for 48 -72 h. Transformation efficiency was calculated as number
of transformants obtained per µg of plasmid DNA [colony-forming unit (CFU) per µg
DNA]. Plasmid isolation from bifidobacteria transformants was optimized from
Francesca et al. [92]. A 10 mL overnight culture of mutant transformed with pDOJHR
or pDOJ-U was used. Plasmid prep was performed using the QIAprep Spin Miniprep
kit (Qiagen) with an additional step for cell lysis. Cells were suspended in Buffer P1
with a final concentration of 30 mg mL-1 lysozyme and incubated for 1hour at 37˚C.
Extracted plasmids were chemically transformed back into E. coli to propagate and
were linearized for identification.
3.2.11 Statistical Analysis
All analyses were performed with GraphPad Software Prism 8.0.1 (GraphPad
Software, Inc., CA, USA). Results were shown as mean ± standard deviation (SD). The
models were checked for normality and variance homogeneity and data transformation
was performed when necessary. Urease activity of multiple strains grown in complex
nitrogen was analyzed through one-way analysis of variance (ANOVA) followed.
Urease activity or growth phenotype of multiple strains cultured from variant media,
including 2% urea, 2% urea plus Ni2+, complex nitrogen, and the negative control was
compared by two-way ANOVA with Tukey’s multiple comparison test. Urease
compliment by purified UreC was analyzed by unpaired two-tailed t-test (WT UreC vs.
boiled WT UreC; Mut UreC vs. boiled Mut UreC) and unpaired two-tailed t-test (WT
UreC vs. Mut UreC), respectively. P < 0.05 was classified as significant.
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3.2.12 Protein Structure Stability Prediction
The structural stability of the mutant UreC was predicted at STRUM
(https://zhanglab.ccmb.med.umich.edu/STRUM/)

using

Mode

I:

Single-point

mutations [93]. The 3D structure of UMA399 UreC was predicted by SWISS-MODEL
(http://swissmodel.expasy.org/)

[94]

and

visualized

by

Chimera

1.13.1

(http://www.rbvi.ucsf.edu/chimera) [95].
3.2.13 Phylogenetic Analysis
The bifidobacterial ureC protein sequences were retrieved from Integrated
Microbial Genomes (IMG) in DOE Joint Genome Institute (JGI; http://img.jgi.doe.gov.
The multiple sequence alignment was done by MAFFT program with default settings
[96]. For the phylogenetic analysis of ureC, the alignments were exported in PHYLIP
format and was imported into PhyML 3.0 [97] where a maximum likelihood
phylogenetic tree was constructed by the SMS (Smart Model Selection) [98] using the
default settings. The phylogenetic tree was visualized using FigTree [99]. Distribution
of urease genes in Bifidobacterium was generated by pheatmap RStudio Team (2018).
RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL
http://www.rstudio.com/. Each gene count was retrieved from the PATRIC- version
3.5.30 Comparative Pathway Service (Wattam, 2016).
3.3 Results
3.3.1 Urease activity is strain-dependent and is elevated by urea and Ni2+.
To detect bifidobacterial ability of hydrolyzing urea, four strains carrying the
urease gene cluster from the subspecies of B. infantis, and B. suis were tested for their
ability to hydrolysis urea and produce ammonia after grown from MRS culture. B.
longum UMA306, which does not possess urease genes, was negative control.
UMA399 shows the highest activity, 10 to 60-fold higher than B. infantis strains.
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Among all B. infantis, UMA302 exhibits higher activity than UMA272 and UMA299.
The latter two strains had no difference in activity (P = 0.2516), as shown in Figure 3.
Phylogeny analysis of the ureC genes in Bifidobacterium suggested a (sub) speciesvariance (Figure 2).
As we found from other bacterial species, the concentration of urea (as the
substrate) and nickel (as the cofactor) may influence the urease activity. To test if the
concentration of urea and nickel will impact bifidobacterial urease, we measured the
urease activity of B. infantis strains grown in complex nitrogen, 2% urea, and 2% urea
with 50 µM Ni2+ (Figure 4). Results showed that the urease activity of all B. infantis
strains in 2% urea is greatly elevated, 4 to10-fold higher than the urease activity in
complex nitrogen. The addition of 50 µM of Ni2+ to the 2% urea media resulted in
higher urease activity than 2% urea media alone. Previously, UMA302 showed
significantly higher urease activity than UMA272 (P = 0.0014) and UMA299 (P =
0.0016) in complex nitrogen (Figure 3). However, this difference could not be
identified from bacterial cells grown in 2% urea and 2% urea with 50 µM Ni2+,
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Figure 2 Maximum likelihood phylogenetic analysis of the bifidobacterial UreC
protein.
Bootstrap values are shown on each node. Number of bootstrap replicates is 100.
Different colors highlight the clustered (sub) species.
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Figure 3 Urease activity among multiple bifidobacterial strains cultured from
complex nitrogen.
UMA272, UMA299, and UMA302 are B. infantis strains; UMA399 is a B. suis strain;
UMA306 is a B. longum strain demonstrated with no urease activity previously (data
not shown) and is used as negative control. Urease activity was detected by the
generation of ammonium in nanomole per milligram protein per min [nmol NH3 min-1
(mg protein-1)]. The bars represent the mean ± SD (standard deviation) of three
individual biological replicates (n = 3). Significant differences between strains were
evaluated by one-way ANOVA and Tukey’s multiple comparison test; NS (not
significant; P > 0.05), ****P < 0.0001.
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Figure 4 Urease activity among multiple bifidobacterial strains cultured from
complex nitrogen.
The bars represent the mean ± SD (standard deviation) of three individual biological
replicates (n = 3). Significant differences between the strains were evaluated by twoway ANOVA and Tukey’s multiple comparison test; P < 0.05 was classified as
significant.
3.3.2 A urease-deficient mutant from B. suis UMA399 was selected and identified
The UMA399 colonies appeared dark green on urease differential agar after
incubation. This is the result of ammonia production. We hypothesized that the urease
mutant would not utilize urea normally and may not produce ammonium, resulting in a
lighter color than the wild-type dark green phenotype. Following this hypothesis, we
performed several trials of chemical mutagenesis to identify mutants by their phenotype
on urease differential agar. The colony exhibits a whitish color was posited to have a
urease mutation and selected for further analysis. As shown in Figure 5A, the mutant
has no urease activity compared to the negative control (P = 0.8137), while the wildtype showed consistent strong activity. The mutant’s growth phenotype is depicted in
Figure 5B, which shows that the mutant did not grow (maximum OD600 nm = 0.103 ±
0.005) in 2% urea media compared to the negative control (maximum OD600 nm = 0.08
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± 0.006; P = 0.8137), in contrast to the wild-type (maximum OD600 nm = 0.273 ± 0.049;
P < 0.0001). These observations indicated that the whitish colony was confirmed as a
urease-deficient mutant.
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Figure 5 Urease activity (A) and growth ability of the mutant strain in 2% urea as
a primary nitrogen source (B).
The B. suis UMA399 mutant strain was selected following EMS mutagenesis. Strains
were all cultured from complex nitrogen. UMA399 is the wild-type strain; UMA306 is
the urease negative strain. In panel (A), the bars represent the mean ± SD (standard
deviation) of three individual biological replicates (n = 3). Significant difference was
evaluated by one-way ANOVA and Tukey’s multiple comparison test; NS (not
significant; P > 0.05), ****P < 0.0001. In panel (B), X axis indicates the time points in
48 hours; Y axis shows the optical density at 600 nm. Growth curves includes, Green:
UMA399 in 2% urea; Red: UMA399 in negative control; Black: mutant in 2% urea;
Blue: UMA399 in negative control. UMA399 is the wild-type strain. The continuous
growth curves display the optical density at 600 nm at each time point by mean ± SD
(standard deviation) from three individual biological replicates (n = 3).
3.3.3 EMS mutagenesis resulted in a nonsynonymous mutation on the mutant ureC
gene
To identify any potential urease gene mutation, the wild-type and the mutant
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genomes were sequenced. SNP-Calling identified 89 nonsynonymous mutations, 36
synonymous mutations, and one deletion on the mutant chromosome. All mutations
were caused by C/G-to-A/T transversions, which corresponded to the known effects of
EMS mutagenesis [100]. As shown in Figure 6A, the urease gene cluster of UMA272
and UMA399 all consist of a urea ABC transporter (urtB/C/D/E plus a urea binding
protein), a nickel ECF transporter (nikM/N/O/Q), urease alpha and gamma subunits
(ureC/ureAB), and accessory proteins (ureE/F/G/D). The distribution of urease genes
in some bifidobacterial strains is shown in Figure 6B). Strains from B. infantis, B. suis,
B. callitrichos, B. kashiwanohense, B. scardovii, B. biavati, and B. subtile harbors a
complete urease gene cluster. It is interesting that all the three B. bifidum strains only
contains a urtE gene, while the rest of urease genes are missing. Also, even though most
urease genes are found in B. infantis, B. infantis 157F-NC does not show existence of
the gene cluster. Throughout the mutant urease gene cluster, only one nonsynonymous
mutation was found in the ureC, encoding the urease alpha subunit. The mutation
caused the conversion of glutamic acid residue to a lysine residue in the protein
sequence. To check if this single-mutation affects the protein stability, the mutant
protein sequence was analyzed by STRUM (structure-based prediction of protein
stability changes upon single-point mutation) (Table 1). The free energy gap difference
(DDG) between the wild-type UreC and the mutant UreC was -1.56, suggesting that the
single-point mutation may cause structural destabilization in the mutant UreC.
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~1.6kb

(A)
B. infantis UMA272
B. suis UMA399
ureC, urease subunit alpha
ureAB, urease subunit gamma beta
ureD/ureE/ureF/ureG, urease accessory proteins

urtA/urtB/urtC/urtD, urea transporter
nikO/nikQ/nikM/nikN, nickel transporter

(B)

* * *

Figure 6 Urease gene cluster of B. suis UMA399 and B. infantis UMA272 (A) and
Distribution of urease genes on variant bifidobacterial genomes (B).
In panel (A), colored arrows denote all the genes on the cluster. In panel (B), X
(horizontal) axis indicates bifidobacterial strains. Y (vertical) axis shows the number of
each urease gene from the cluster, from up to down: urtE, ureAB, ureC, ureF, ureG,
ureE, ureD, urtB, urtD, urtC, urtA. The legend scale on the right indicate the gene
counts found on the genome. Red: 1; Navy: 0. The white stars indicated the three B.
bifidum strains each has one urtE gene. Groups of bifidobacteria with a complete urease
gene cluster, a truncated urease gene cluster or without the gene cluster were marked
in red, green and blue frame at the bottom.
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Table 1 Prediction of wild-type UreC stability changes upon the single-point
mutation by STRUM.
The mutation on the UreC caused the Glutamic acid (E) 343 to Lysine (K). The ddG
OR DDG are the changes of Gibbs free-energy gap between the wild-type UreC and the
mutant UreC. A value of DDG under zero suggested that the single-point mutation
caused a destabilization.
Position
343

Wild-Type
E

Mutant type
K

ddG
-1.56

3.3.4 Purified wild-type UreC restored urease activity after incubation with
mutant lysates
To test if ureC mutation would cause protein-level functional deficiency, we
expressed and purified both the wild-type UreC and the mutant UreC in vitro. The
purified UreC were tested in a urease assay in vitro. Cell free lysate from the mutant
strain was incubated with both purified UreC. After incubation, the wild-type UreC was
able to restore urease activity to a lower level (Figure 7). The mutant UreC showed no
difference from the negative control (P = 0.061), indicated its deficiency. This result
suggested that the UreC was necessary for bifidobacterial urease function.
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Figure 7 Urease activity was restored by purified UreC.
Mut-UreC: purified UreC from the mutant; WT-UreC: purified UreC from wild-type;
H-WT/Mut-UreC means heated UreC, which is used as negative control. Purified UreC
was incubated with the mutant cell-free lysates in vitro, supplemented with urea. The
bars represent the mean ± SD (standard deviation) of three independent experiments (n
= 3). Significant differences were evaluated by t-test; NS (not significant; P > 0.05),
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P < 0.0001.

3.3.5 Purified mutant UreC is different in confirmation vs. WT UreC
The predicted protein structure of wild-type UreC from UMA399 is shown in
Figure A3. Two green nickel ions were niched inside the red histidine, lysine and
aspartate residues nearby. This tertiary structure predicts the metallocentre of the UreC
as a monomer. Based this prediction, Ni2+ is the cofactor of UreC. UreC (alpha subunit)
might bind to Ni2+ for urease maturation and will thus cause a conformation change
during binding to nickel. The curve indicates SYPRO orange fluorescence intensity
versus temperature. During UreC binding to Ni2+, the protein would unfold and expose
its hydrophobic patches, leading to a strong emission of fluorescent light of 610nm, and
thus indirectly indicating configuration difference. The curved showed an excited peak
from 50,000 to 80,000 (A.U.) at 610 nm when the wild-type UreC was incubated with
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Ni2+. While the incubation of mutant UreC with Ni2+ showed no emission peak.
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Figure 8 Configuration change of the wild-type UreC and mutant UreC detected
by differential scanning fluorimetry.
The curve shows the SYPRO orange fluorescence intensity versus temperature during
the incubation of purified UreC with Ni2+. While the protein subunit folded, the
fluorescence intensity is excited by light of 492 nm. The unfolding of the protein or the
large emission of the 610 nm by the fluorescence indirectly suggested a configuration
change.
3.3.6 Transformation of pDOJ-U into the mutant complement urease activity
To restore urease activity in vivo, we cloned ureC with its promoter from the
wild-type strain B. suis UMA399 into the shuttle vector pDOJHR. As shown in Table
2, the transformation of pDOJHR and pDOJ-U to the mutant gave an efficiency of
(1.375 ± 0.71) ´ 102 and (1.25 ± 0.54) ´ 102 (CFU µg-1 DNA), respectively. Urease
assay and growth in 2% urea were tested on mutants harboring the pDOJHR and pDOJU vectors (Figure 10 and Figure 11). The mutant with pDOJ-U vector showed the
same level of urease activity (219. 041 ± 69.081) [nmol NH3 min-1 (mg protein)-1] to
the wild-type (237.055 ± 59.463) [nmol NH3 min-1 (mg protein)-1] (P = 0.9838). The
mutant with the pDOJHR vector did not exhibit an activity compared to the negative
control (Figure 10). Growth curve in Figure 11 depicts a positive utilization of 2%
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urea by the mutant containing pDOJ-U, with a maximum OD600 nm = 0.209 ± 0.0147,
significantly higher than its negative control (OD600 nm = 0.079 ± 0.004; P < 0.0001)
and same as the wild-type (OD600

nm

= 0.273 ± 0.495; P = 0.5877). The mutant

containing pDOJHR in 2% urea reached a maximum OD600 nm = 0.085 ± 0.01327, with
no difference to its negative control (OD600 nm = 0.068 ± 0.008; P = 0.9993). Growth
levels of all strains in complex nitrogen were similar, indicating that the shuttle vectors
did not induce any toxic side effects. The results of these experiments demonstrate the
ability to restore urease activity in vivo by expressing ureC only, indicating that the loss
of urease function in the mutant was likely due to this mutation.
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Figure 9 Construction of the UreC expression shuttle vector pDOJ-U.
The ureC fragment indicated by pattern-filled arrow was cloned in between the EcoRI
sites on the shuttle vector pDOJHR, forming pDOJ-U.
Table 2 Electro-transformation efficiency.
pDOJHR and pDOJ-U were both transferred into the B. suis UMA399 mutant strain.
Results were represented by mean ± SD (standard deviation) from three independent
experiments (n = 3). Transformation efficiency was calculated as number of
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transformants obtained per µg of plasmid DNA in unit colony-forming unit (CFU) per
µg DNA.
Host

Plasmid

Transformation efficiency (CFU µg-1 DNA)

Mutant
Mutant

pDOJHR
pDOJ-U

(1.375 ± 0.71) ´ 102
(1.25 ± 0.54) ´ 102
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Figure 10 Urease activity was complemented by expressing the wild-type ureC
gene in the mutant.
Strains were cultured in complex nitrogen. Mutant + pDOJHR: mutant transferred with
pDOJHR; Mutant + pDOJ-U: mutant transferred with pDOJ-U (ureC from wild-type
cloned in pDOJHR). UMA399 is the wild-type strain; UMA306 is the urease negative
strain. The bars represent the mean ± SD (standard deviation) of three individual
biological replicates (n = 3), with the exception of pDOJ-U and UMA399 (n=4).
Significant differences were evaluated by one-way ANOVA and Tukey’s multiple
comparison test; NS (not significant; P > 0.05), ****P < 0.0001.
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Figure 11 Growth phenotype complemented by pDOJ-U.
Strains were cultured in 2% urea and negative control. Mutant + pDOJHR: mutant
transferred with pDOJHR; Mutant + pDOJ-U: mutant transferred with pDOJ-U (ureC
from wild-type cloned in pDOJHR). UMA399 is the wild-type strain. In panel (A), the
bars represent the maximum optical density at 600 nm of each strain in mean ± SD
(standard deviation) of three individual biological replicates (n = 3). Growth was
compared by two-way ANOVA and Tukey’s multiple comparison test; NS (not
significant; P > 0.05), ****P < 0.0001. Panel (B) shows the entire growth pattern. The
continuous growth curves display the optical density at 600 nm at each time point by
mean ± SD (standard deviation) from three individual biological replicates (n = 3).
3.4 Discussion
The significant proportion (~15%) of urea as a nitrogen source in human milk
provides a secondary nutrient reservoir if the infant microbiota utilizes it and make it
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absorbable by the infant, as 95% of proteins in human milk is considered not fully
nutritionally available to the
infant until 6 weeks postpartum [101]. It has been proposed that urea can be salvaged
via breakdown in the colon, incorporated into microbial proteins, and release as amino
acids that can be absorbed by gut epithelial cells and utilized for host metabolism. Since
Bifidobacterium are predominant gut colonizers in newborns, it is particularly
significant that these microbes are capable of degrading urea and thereby aiding
nitrogen recycling to the host. Historically, very limited studies have focused on urease
function in Bifidobacterium. The underlying mechanisms of this process are poorly
understood. This current study serves as a starting point for future analysis regarding
bifidobacterial urease and its potential impacts on infant health and early development.
The ureC amino acid sequence aligned among bifidobacterial strains from 12
subspecies indicates a very high similarity (data not shown). Among the genus of
Bifidobacterium, only some species, (B. aesculapii, B. biavatii, B. callitrichos, B.
infantis, B. kashiwanohense, B. suis, B. scardovii, B. subtile) harbor a complete urease
gene cluster including a urea transporter, a nickel transporter, urease alpha and
beta/gamma subunits, and urease accessory proteins. Interestingly, many of the species
were isolated from human infant or non-human primates including baby common
marmoset and cotton-top tamarins (data not shown). The B. suis strain UMA399 in this
study was isolated from a rhesus macaque infant. Some other Bifidobacterium species
such as B. bifidum only contain one urea transporter gene on its genome, which may be
the result of gene horizontal transfer during adaptation to the host or environment. As
human milk provides the first and sole nutrient for infant, whether human milk urea is
an evolutionary retention force for urease genes within bifidobacterial species still
needs further discussion.
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In this study, urease activity was detected among several bifidobacterial strains
including B. infantis, B. suis, and B. longum strains. A diversity of urease activity was
also detected from complex nitrogen, 2% urea, and 2% urea plus Ni2+ as the growth
media. Notably, B. suis UMA399 exhibits a very strong activity even in complex
nitrogen, which is consistent with a previous study [82]. However, contrary to another
previous study [81], we found that urease in bifidobacteria is significantly elevated by
urea and nickel compared to its basal expression in complex nitrogen. Nickel, as the
cofactor of urease, its function has been widely studied in many bacterial ureases. As
we predicted the protein structure of the wild-type UreC, the model gave a structure
with Ni2+ niche similar to the known structures. While nickel detected from our growth
medium is only in trace amounts (data not shown), its presence has been identified in
human milk during lactation, differentiating between individuals [102-105]. As we
detected, a concentration of 50 µM Ni2+ elevated the urease activity in Bifidobacterium.
The existence of nickel in human milk might be a potential stimulator for urease
function. Targeted mutagenesis has been performed on many bacterial urease genes e.g.,
H. pylori etc. In this study, we screened a mutant from B. suis UMA399, its ureC was
knocked out by chemical mutagenesis.

However, our study suggested that the

substitution of the key residue - 343 Glutamine affects the maturation of an active
urease, resulting a configuration difference and deficient urease activity.
Transformation is an essential technique for functional analyses of genes in
bacteria. So far, the transformation efficiency in the genus of Bifidobacterium is still
generally low, with a median efficiency of 103 CFU per µg plasmid DNA mainly by
electroporation

[34].

The

electro-transformation

protocols

developing

for

bifidobacteria still require strain-dependent methodology [31]. To the best of our
knowledge, there are no other reports of Bifidobacterium longum subsp. suis

41

transformation. The shuttle vector used in this study, pDOJHR, has been previously
used in B. longum [26]. Accordingly, our transformation employed for the B. suis
UMA399 mutant strain was optimized using pDOJHR. Key experimental conditions
for this transformation included using mid-logarithmic-phase cells (OD600 nm = 0.4 0.6), a washing buffer with high-amount sucrose (0.5 M), and a 30 - min preincubation
before the electric pulse (25 µF, 200 W, 2.2 kV), which is widely used in most recent
studies on bifidobacteria. Interestingly, we found that using just plain MRS as the
growth and recover medium, without extra carbohydrates, gave an adequate
transformation efficiency (~102 CFU per µg DNA). Although other methods include
adding high concentrations of sugars (sucrose, raffinose, fructo-oligosaccharides etc.)
into the growth medium [24, 26, 29, 32], our result suggested that extra sugar might not
be essential under every circumstance. Previous researchers have successfully created
bifidobacteria mutants using plasmid artificial modification techniques. The PAM
method has shown its efficacy in a few strains including Bifidobacterium adolescentis
ATCC15703 and Bifidobacterium breve UCC2003. As there is still a barrier for making
a targeted mutation in our strain, EMS mutagenesis was used in this study to make the
urease mutation. Since EMS mutagenesis is random, the odds of creating the desired
gene mutation are very low. A more applicable and wild-spectrum genetic tool for
inducing gene mutations is essential for future bifidobacterial research.
3.5 Conclusions
To our knowledge, this is the first study on bifidobacterial urease gene function.
We demonstrated that the E343K mutation on the UreC lead to configuration and
functional change, which impedes its catalyzing activity during the hydrolysis of urea.
Thus, UreC is essential for the bifidobacterial urea utilization phenotype. This further
adds to scientific knowledge regarding host-microbiome interaction catalyzed by

42

human milk.
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CHAPTER 4
EXPLORING L-CYSTEINE AUXOTROPHY IN BIFIDOBACTERIUM

4.1 Introduction
Cysteine and methionine are the two proteinogenic and sulfur-containing amino
acids that are essential for bacteria [106]. Specifically, cysteine has been used in
bifidobacterial culture as a necessary growth supporter as well as an redox potential
reducer [107]. Cysteine has been found in human milk as one of the free amino acids
[108], as well as in human intestines as a metabolite from the gut microbes [109].
Previous studies found that many species of Bifidobacterium, including B.
infantis, B. bifidum, B. breve are cysteine auxotrophic, in which cysteine biosynthesis
pathways are inactive. Pathways of cysteine and methionine biosynthesis have been
well clarified in E. coli.
There are two cysteine biosynthesis pathways. In the first pathway, cystathionine betasynthase (CBS) converts serine and homocysteine (a product of methionine degradation)
to form cystathionine in an irreversible reaction. The cystathionine is then degraded by
cystathionine gamma-lyase (CGT) to cysteine. In the other pathway, serine is converted
to O-acetyl-serine by serine acetyltransferase (cysE). With the incorporation of
hydrogen sulfide, and catalysis of cysteine synthase (cysK), O-acetyl-serine is
converted to cysteine and acetate [110].
For Bifidobacterium, the cysteine/methionine biosynthesis pathways are poorly
characterized. Most bifidobacterial strains behaves cysteine prototrophic, including B.
infantis, B. bifidum [111-113]. However, cysteine auxotrophy is not a common feature
of all the species in the genus Bifidobacterium. Representatives of some species such
as B. boum, B. minimum, B. pullorum, B. ruminantium, B. saguini and B. scardovii
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showed slightly growth without adding cysteine [113]. The cysteine auxotroph is
mainly due to the lack of key enzymes in its biosynthesis pathways. In Lactobacillus,
the function of cysE, and cysK needed for cysteine synthesis from serine was confirmed
by complement the E. coli cysE and cysK mutants. [110, 114]. For Bifidobacterium,
studies on cysteine auxotrophy are very limited. The only report on the cysteine
auxotrophic behavior is on B. bifidum PRL2010. Results indicated that genes needed
for sulfate transport and reduction to sulfide are lacking, which is common in
Bifidobacterium [115]. The transcription of genes involved in cysteine and methionine
metabolism was not stimulated by the access of these amino acid residues. For other
bifidobacterial (sub) species such as B. infantis, its cysteine auxotrophic behavior has
not been characterized. B. infantis is predominant constituent in the infant gut due to
their capacity growth on human milk oligosaccharides. It will be important to
investigate how B. infantis utilizes cysteine and its nutrients requirement to further
revealing its role in the infant gut during their early development.
In this chapter, we investigated the auxotrophic behavior of Bifidobacterial
strains, by comparing to some cysteine prototrophic strains of the species B. boum.
We performed in silico analysis on genes involved in their cysteine and methionine
metabolism together with transcription level quantification. Grow assay in variant
nitrogen sources was monitored to clarify the phenotypes related with cysteine
utilizations.
4.2 Material and Methods
4.2.1 Bacteria and Culture Conditions
B. infantis UMA272, B. suis UMA399, B. scardovii JCM12489, B. boum LMG
10736, will be used for this study. Single colonies of bifidobacteria were grown
overnight in De Man-Rogosa-Sharpe (MRS) broth (Difco, USA) supplemented with
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0.05% (wt/v) L-cysteine and incubated overnight at 37˚C in a Coy anaerobic chamber
(Coy Laboratory Products, MI) with an atmosphere of 90% N2, 5% CO2 and 5% H2.
4.2.2 Construction of the CysK and MetB Expression Vector
The E. coli-Bifidobacterium shuttle vector pDOJHR was used for this study.
The 195 bp upstream and 60 bp downstream region flanking the cystathionine betasynthase (EC 4.2.1.122) (cysK) and cystathionine gamma-lyase (EC 2.5.1.48) (meB)
coding sequence (CDS) from the genome of B. suis UMA399 was amplified by primer
CYS-F/R, in which EcoRI sites were incorporated. The amplicon and pDOJHR were
digested with EcoRI, ligated by T4 DNA ligase (NEB, USA), and transferred to E. coli
strain NEB 5-alpha (NEB, USA). The insert within the plasmid was confirmed by
sequencing at Eton Bioscience (Boston, USA) to make sure that there is no mutation.
The pDOJHR vector with the cysK and metB gene was named pDOJ-cysK-metB, as
shown in Figure A5 drawn by SnapGene (from GSL Biotech; available at
snapgene.com).
4.2.3 Electroporation
A 5% (v/v) overnight culture of the B. infantis UM272 strain was used to
inoculate 40 mL MRS (Difco, USA) supplemented with 0.05% L-cysteine and
incubated at 37˚C until an OD600 nm of 0.4-0.5 was reached. Cells were collected at
4,696 ´ g for 15 min at 4˚C, then washed 3 times with 30 mL ice-cold electroporation
buffer [10% (v/v) glycerol and 0.5 M sucrose]. Cells were resuspended in 1 mL buffer
in a microcentrifuge tube, pelleted again, and resuspended in 1/250 (v/v) of the original
culture. For each transformation, 50 µL of the cell suspension and 400 ng of plasmid
DNA were mixed and incubated on ice for 30 min, then transferred to a pre-chilled 1
mm disposable cuvette. A voltage electric pulse was delivered through a Gene Pulser
(Bio-Rad) at 25 µF, 200 W and 2.2 kV. Cells were immediately resuspended with 950
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µL of MRS (Difco, USA), transferred into a 15 mL falcon tube, and recovered
anaerobically for 3 hours at 37˚C. After which, cells were diluted and plated on
aluminum foil-wrapped MRS plates supplemented with 5 µg mL-1 chloramphenicol and
incubated anaerobically at 37˚C for 48-72 h. Plasmid isolation from bifidobacteria
transformants was optimized from Francesca et al. [92].
4.2.4 Growth Dependence on Nitrogen and Sulfur Source
The growth phenotype of cells in variant nitrogen sources was monitored in a
96-well plate. Cells from overnight MRS broth culture were used to inoculate at 1%
(v/v) into a basal medium adding 0.2% urea, 0.02%-0.05% glutamine, cysteine or
methionine as the sole nitrogen source. The base medium contained 2% D-glucose, 0.2%
potassium phosphate dibasic anhydrous, 0.5% sodium acetate anhydrous, 0.02%
magnesium sulfate heptahydrate, 0.005% manganese (II) sulfate monohydrate, 0.1%
Tween 80. The basal medium with 1% peptone, 0.8% yeast extract, 0.1% ammonia
citrate and 0.05% L-cysteine was regarded as a positive control; The basal media that
only contained carbon source was regarded as negative control. The growth assay was
conducted at 37˚C for up to 28 hours in a microplate spectrophotometer (BioTek, USA)
placed within the anaerobic chamber. Reads were performed with shaking at intervals
of 5 min to detect optical density at 600 nm. Each strain was measured in biological
triplicate with three technical repeats. For growth with various sulfur compounds, the
0.02% magnesium sulfate heptahydrate and 0.005% manganese (II) sulfate
monohydrate in the basal medium were replaced by 0.02% magnesium chloride
hexahydrate and 0.005% manganese (II) chloride tetrahydrate respectively. The new
basal medium containing either 0.05% methionine or 0.05% methionine plus 0.7 mM
sodium or both was inoculated with B. boum LMG10736 (1% v/v). Basal medium with
sulfur source excluded was used as negative control.
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4.2.5 Mutant generation by Ethyl methane sulfonate (EMS)
Bifidobacterial cells from a 4 mL of overnight culture were spun down and
resuspended in 4.75 mL phosphate buffer [pH7.2]. A 250 µL of EMS (99%) was added
to reach a final concentration of 5% (v/v). The mixture was incubated at 37˚C for 30
min. Cells were pelleted again and washed 3 times with fresh MRS. Cell suspension in
5 mL fresh MRS was diluted to 25% of the original concentration and grown overnight.
Dilutions of 100 µL overnight mutagenized cultures were spread on a cysteine
prototroph selective agar. The selective agar was made from a base agar (2% D-glucose,
0.2% potassium phosphate dibasic anhydrous, 0.5% sodium acetate anhydrous, 0.02%
magnesium sulfate heptahydrate, 0.005% manganese (II) sulfate monohydrate, 0.1%
Tween 80) supplemented with 0.1% methionine. The base agar was used as negative
control. The basal agar with 1% peptone, 0.8% yeast extract, 0.1% ammonia citrate and
0.05% L-cysteine was regarded as a positive control; Plates were incubated
anaerobically at 37˚C for 2 weeks.
4.2.4 Multiple Sequence Alignment
The protein sequences of the cystathionine beta-synthase (EC 4.1.2.22) were
retrieved from Integrated Microbial Genomes (IMG) in DOE Joint Genome Institute
(JGI; http://img.jgi.doe.gov). Multiple alignment was visualized by the Geneious Prime
2019. 2.1. (https://www.geneious.com)
4.2.5 Distribution of cysteine and methionine biosynthesis genes in Bifidobacterium
Heatmaps were generated by pheatmap RStudio Team (2018). RStudio:
Integrated

Development

for

R.

RStudio,

Inc.,

Boston,

MA

URL

http://www.rstudio.com/. Each gene count was retrieved from the PATRIC- version
3.5.30 Comparative Pathway Service (Wattam, 2016). Cysteine and methionine
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biosynthesis pathways were referred to E. coli and Bacillus subtilis from MetaCyc
(http://metacyc.org) [116].
4.2.6 Statistical Analysis
All analyses were performed with GraphPad Software Prism 8.0.1 (GraphPad
Software, Inc., CA, USA). Results were shown as mean ± standard deviation (SD). The
models were checked for normality and variance homogeneity and data transformation
was performed when necessary and was analyzed through one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test. P < 0.05 was classified as
significant.
4.3 Results
4.3.1 UMA272, UMA399 and JCM12489 are cysteine auxotrophic strains.
To evaluate the utilization of cysteine, methionine and 2% urea as the sole
nitrogen source by B. infantis UMA272, B. suis UMA399 and B. scardovii JCM12489,
we measured their growth in the corresponding culture as shown in Figure 12. Panel A
shows that B. suis UMA399 was not able to utilize 2% urea as a sole nitrogen source
compared to the control, when adding cysteine, it grew significantly higher. Panel B
shows that B. infantis UMA272, B. suis UMA399 and B. scardovii JCM12489 did not
grow in methionine compared to the negative control. Only when cysteine was added
in growth medium, a significant higher growth was observed. The addition of
methionine to cysteine promoted growth compared to that in cysteine as the sole
nitrogen source. This interestingly suggested that these bacterial strains are only able
to use methionine when cysteine is in the medium.
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Figure 12 Growth phenotype of B. infantis UMA272, B. suis UMA399 and B.
scardovii JCM12489 in cysteine and methionine and urea.
Panel A: B. suis UMA399 utilization of urea. Panel B: B. infantis UMA272, B. suis
UMA399 and B. scardovii JCM12489 utilization of cysteine and methionine. The bars
display the final optical density at 600 nm by mean ± SD (standard deviation) from
three individual biological replicates (n = 3). cys, cysteine; met, methionine; cys + met,
cysteine + methionine. NS (not significant; P > 0.05), ****P < 0.0001.
4.3.2 Truncated CysK and MetB in UMA272 is not responsible for cysteine
auxotrophy
As we were compared the genes related with cysteine biosynthesis in variant
bifidobacterial strains, we found that the protein sequence of cystathionine betasynthase (EC 4.2.1.22) (cysK) and gamma-lyase (EC 2.5.1.48) (metB) genes in B.
infantis UMA272 are truncated as shown in Figure 13 (first sequence from the top).
Except for UMA272 and UMA399, all other strains were tested to be cysteine
prototroph [117]. Growth results showed that B. infantis UMA272 and B. suis UMA399
were both cysteine auxotroph, even though the cystathionine cysK and metB genes in
UMA399 were of highly similar to the other cysteine prototrophic strains. However,
for UMA272, both its cysK and metB genes were truncated (data only shown). To figure
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out if the truncated cysK and metB genes lead to the cysteine auxotrophy of UMA272,
we cloned the cystathionine cysK and metB genes from UMA399 into the shuttle vector
pDOJHR (pDOJ-cysK-metB), transferred it into UMA272, and tested the growth of
UMA272 with and w/o the pDOJ-cysK-metB in cysteine and methionine. Results in
Figure 14 shows that B. infantis UMA272 with pDOJ-cysK-metB was not able to grow
in methionine as the sole nitrogen source compared to the negative control. This
suggested that other pathways or gene regulations besides the expression of
cystathionine beta-synthase (EC 4.2.1.22) and gamma-lyase (EC 2.5.1.48) might be
needed to enable cysteine biosynthesis in B. infantis UMA272.

Figure 13 Multiple alignment of cystathionine beta-synthase (EC 4.2.1.22) protein
sequence in variant species of Bifidobacterium.
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Sequence similarity is indicated by green, olive and red bar chart. (Green: 100%
identity; Olive: 30% - 100% identity; Red: less than 30% identity). Conserved to nonconserved residues are highlighted by black, dark grey, light grey and white. (Black:
100% similar; dark grey: 80% - 100% similar; Light grey: 60% - 80% similar; White:
less than 60% similar). The strains from up to down are: B. infantis UMA272, B.
minimum DSM20102, B. suis UMA399, B. boum DSM20432, B. breve JCM7017, B.
minimum LMG11592, B. scardovii LMG21589, B. pullorum LMG21816, B. pullorum
DSM20433, B. saguini DSM23967.
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Figure 14 Growth phenotype of B. infantis UMA272 with or without pDOJ-cysKmetB in cysteine and methionine.
The bars display the final OD600 nm by mean ± SD (standard deviation) from three
individual biological replicates (n = 3). cys, cysteine; met, methionine; cys + met,
cysteine + methionine. pDOJHR-cysK-metB, pDOJHR carrying the cystathionine betasynthase (EC 4.2.1.22) and gamma-lyase (EC 2.5.1.48) genes from B. suis UMA399.
NS (not significant; P > 0.05). ***P = 0.0002, ****P < 0.0001.
4.3.3 LMG10736 is a cysteine prototroph
Utilization of cysteine, methionine and glutamine by B. boum LMG10736 is
shown in Figure 15. This strain grew in both sulfur-containing amino acids cysteine
and methionine. Its growth in glutamine as a sole nitrogen source was not significant.
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This confirmed that B. boum LMG10736 is a cysteine prototroph as it can use
methionine as a sole nitrogen source for its growth.
(A)

L-Cysteine

1.5

(B)

OD600nm

OD600nm

0.9

0.3

L-Methionine

1.2

1.2

0.6

1.5

****
****
****

0.9
****
**

0.6
0.3

**
***

0.0

(C)

0.30

OD600nm

0.25
0.20

no

no

n
0. itro
02 g
0. % en
0 m
0. 3% et
04 m
co
m 0.0 % et
pl 5 m
ex % e
ni m t
tro et
ge
n

n
0. itro
02 g
0. % en
0 c
0. 3% ys
co
0
m 0 4% cys
pl .0 c
ex 5% y
ni c s
tro ys
ge
n

0.0

0.05% glut
0.04% glut
0.03% glut
0.02% glut
no nitrogen

0.15
0.10
0.05
0 2 4 6 8 10 12 14 16 18 20 22 24
Time (h)

Figure 15 Growth phenotype of B. boum LMG 10736 in L-cysteine, methionine
and glutamine.
B. boum LMG10736 was cultured in 0.02-0.05% cysteine (panel A), methionine (panel
B), glutamine (panel C). The bars display the final OD600 nm by mean ± SD (standard
deviation) from three individual biological replicates (n = 3), analyzed by 2way
ANOVA followed by Tukey’s multiple comparison test (**P = 0.0021, ***P = 0.0002,
****

P < 0.0001). The continuous growth curve of B. boum LMG10736 in glutamine

shows optical density at 600 nm at each time point by mean ± SD (standard deviation)
from three individual biological replicates (n = 3). cys, cysteine; met, methionine; glut,
glutamine.
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4.3.4 LMG10736 can utilize methionine as both nitrogen and sulfur source but
cannot utilize in vitro sulfate or sulfide as sulfur source.
The predicted biosynthesis pathway of cysteine and methionine needs the
incorporation of sulfide at certain steps as shown in Figure 17. In bacterial cells, sulfide
can be obtained by reducing sulfate, as well as from degradation of sulfur-containing
amino acids, such as cysteine or methionine. To test if methionine can be utilized by B.
boum LMG10736 as a sulfur source, we replaced the MnSO4 and MgSO4 with MnCl2
and MgCl2, added methionine as the sole nitrogen and sulfur source. Meanwhile, we
also added sulfide in addition to methionine to see if the in vitro sulfide would stimulate
the growth of LMG10736. Results in Figure 16 shows that B. boum LMG10736 was
not able to utilize sulfide as a sulfur source, as it exhibited a much lower growth
compared to 0.05% methionine. Compared to the group without nitrogen and any sulfur,
the control group without nitrogen that contained sulfates in the growth medium did
not show significant growth neither, indicating that B. boum LMG10736 was not able
to utilize sulfates besides sulfide. While in 0.05% methionine as both nitrogen and
sulfur source, B. boum LMG10736 grew the best. This confirmed the sulfur containing
amino acid methionine is incorporated into sulfur metabolisms.

54

OD600nm

0.15

0.05% met
0.05% met+0.7mM sulfide
no nitrogen and sulfur
no nitrogen

0.10

0.05

0.00
0 2 4 6 8 10 12 14 16 18 20 22 24
Time (h)

Figure 16 Growth phenotype of B. boum LMG 10736 in modified medium that
contained sulfur containing amino acids or sulfide.
B. boum LMG 10736 was cultured in 0.05% methionine, 0.05% methionine with
0.7mM sulfide. The growth curves display the optical density at 600 nm by mean ± SD
(standard deviation) from three individual biological replicates (n = 3).
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Figure 17 Predicted pathways of cysteine and methionine biosynthesis in
Bifidobacterium.
Red marked the start/key metabolite in each pathway. The blue boxes marked the end
metabolite in each pathway. Arrows shows the direction of reactions, connecting each
middle metabolite. EC number of the enzyme in each reaction is marked in red with
description and gene symbol below.
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(A)

(B)

Figure 18 Distribution of cysteine and methionine biosynthesis genes in B. infantis
UMA272 (ATCC15697), B. suis UMA399, B. boum LMG10736, B. scardovii
JC12489.
The legend scale on the right indicate the gene counts found on the genome. Red: 6,
Light blue: 2; Dark blue: 1; Navy: 0. Y axis shows the participated enzymes with EC
number; X axis shows the strain names.
4.3.5 Predicted cysteine biosynthesis pathways in bifidobacterial strains
The predicted biosynthesis pathways of cysteine and methionine is shown in
Figure 17, and the distribution of genes participated in these pathways on
bifidobacterial genomes is shown in Figure 18. According to prediction, cysteine can
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be directly synthesized from serine (Figure 17A) or from methionine degradation
(Figure 17C). For the serine pathway, the enzyme - Serine acetyltransferase (EC
2.3.1.30) is missing in all these four strains (Figure 18A). B. infantis UMA272
(ATCC15697), B. suis UMA399, B. scardovii JCM12489 are cysteine prototroph as
confirmed previously. Interestingly, all these bifidobacterial strains except for B.
scardovii JCM12489 were found to contain all the genes for the methionine degradation
pathway on their genomes (Figure 18B). For methionine biosynthesis pathway, the
incorporation of cysteine is a necessity.
4.4 Discussion
For Bifidobacterium, the mechanisms underlying cysteine auxotrophy are
poorly understood. This study tested several bifidobacterial strains including B. infants
UMA272, B. suis UMA399, and B. scardovii JCM12489, B. boum LMG10736. on their
ability to utilize non-cysteine sole nitrogen sources, as well as sulfur sources. Cysteine
and methionine are two sulfur-containing, proteinogenic amino acids, which are
essential for bacterial growth. The cysteine/methionine biosynthesis pathway has not
been clarified in the genus of Bifidobacterium. In this study, we combined growth test
and genomic analysis to provide putative interpretations to the auxotrophic behavior in
Bifidobacterium.
To analyze the cysteine/methionine biosynthesis genes in these bifidobacterial
strains, we referred to the similar pathways from well-studies bacterial strains including
E. coli and Bacillus subtilis. For cysteine synthesis, we first checked the pathway in
which serine is synthesized to cysteine. Since the first reaction enzyme is missing, we
then predicted this pathway is not functional. The missing of serine pathway was also
found in many other bifidobacterial strains as we checked their genome (data not
shown).
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Cysteine may also be produced by methionine degradation. We found that genes
in this pathway are existing in B. infantis UMA272, B. suis UMA399 and B. boum
LMG10736. As we identified, B. infantis UMA272 has a truncated cystathionine betasynthase (EC 4.2.1.22) (cysK) and cystathionine gamma-lyase EC 2.5.1.48 (metB) but
is not the only reason for its auxotrophic behavior. In contrast, B. suis UMA399 has
complete genes for every enzyme (data not shown) similar to the prototrophic strain B.
boum LMG 10736 but is still cysteine auxotrophic. Thus, we predicted that for
UMA272 and UMA399, their auxotrophic behavior can be related with gene silencing
on the methionine degradation pathway on transcriptional or translational level. For, B.
scardovii JCM12489, the missing of DNA (cytosine-5-)-methyltransferase might be the
reason for its auxotrophic behavior.
As we found, sulfur metabolisms are along with the biosynthesis sulfurcontaining amino acids cysteine and methionine. Many bacteria can obtain sulfide from
sulfate reduction. However, this is a rare phenotype in Bifidobacterium. The cysteine
prototrophic strain B. boum LMG10736 did not show utilization of either sulfate or
sulfide and no sulfur transport system was found on its genome (data not shown). This
indicated that B. boum LMG10736 probably utilized the organic sulfur that from the
backbone of methionine to synthesize cysteine and support its growth. The absence of
sulfur transport and reduction to sulfide is common in Bifidobacterium [115], as was
also found in B. bifidum PRL2010. The missing of these genes in Bifidobacterium
might be related with adaption to the specific niche. Whether there is an absorbance of
non-organic sulfur sources (sulfides, sulfates) or organic sources (cysteine, methionine)
by Bifidobacterium from the surrounding environment and gut commensals deserves
future investigation.
4.5 Conclusions
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This study provides initial insights for cysteine auxotrophic behavior in some
bifidobacterial species. Future work on transcriptomics, proteomics or metabolomics is
still needed to depict the complete cysteine and methionine biosynthesis pathway in
Bifidobacterium. This preliminary data may also open a new avenue of research for
understanding how auxotrophic gut commensals may acquire essential nutrients from
the gut environment.
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CHAPTER 5
FUTURE WORK

In chapter 3, the bifidobacterial urease function was investigated by
characterizing a ureC mutant generated from Bifidobacterium long subsp. suis
UMA399. The protein structural analysis of the wild-type UreC and the mutant UreC
can be further analyzed in the future. First part will be crystallization of both UreC
accompanied by detailed protein structure analysis by protein mass spectrometry. The
wild-type UreC and the mutant UreC incubated with N2+ showed a configuration
difference that may be related with nickel-binding. To deeply explain the configuration
difference, inductively coupled plasma mass spectrometry (ICP-MS) can be applied to
further test how much nickel ions each protein can bind to, which will evaluate the
nickel-binding ability between the wild-type UreC and the mutant UreC.
It is also interesting to study how urea utilization will impact the infant gut
microbial community dynamics, as well as the profile of metabolites. For this purpose,
a bioreactor system simulating the fermentation of gut environment can be used.
Bacteria isolated from infant fecal samples can be incubated with the growth culture
supplemented with urea in the bioreactor for tracking growth. Metabolites in the culture
from the bioreactor can be sent for HPLC analysis. 16S rDNA sequencing can be
conducted on bacteria from the infant fecal samples as well as various fermentation
point to check the bacterial community dynamics.
In addition, a targeted mass spectrometry-based metabolic profiling study can
also be performed to study urea salvaging in animal model. Blood samples will be taken
from the germ-free mice inoculated with bifidobacteria and fed with a designed diet
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supplemented with isotope-labelled urea. MS-based equipment will be used to identify
the plasma protein from the plasma to track urea salvaging.
In chapter 4, the cysteine auxotrophic behavior in bifidobacterial strains was
explored based on growth assay and genomic analysis. It is also important to study the
transcriptional level change of cysteine/biosynthesis genes either by qRT-PCR or by
RNAseq. For higher-quality RNA extraction, a chemically defined medium that
contains every single amino acid with exclusion of methionine or cysteine will be useful
to increase bacterial growth and cell mass. Total RNA will be extracted from
bifidobacterial cells cultured from cysteine, methionine or both. Putative genes in
cysteine and methionine biosynthesis pathways including metA, metB, metC, metC,
metE, cysE, cysK can be targets to test their expression level change corresponding to
the nitrogen source.
In addition to transcriptional level, a proteomic experiment can also be
performed to verify the protein profiles associated with cysteine biosynthesis.
Bifidobacterial strains that are cysteine prototrophic can be grown in isotope-labeled
methionine as a sole nitrogen source. Cell free lysate can be extracted from the cells to
identify where the labeled methionine is incorporated into in the pathways that
synthesizing cysteine, such as the methionine degradation pathway. Products in the
middle of the reaction can also be detected to depict a concise cysteine/biosynthesis
pathway for Bifidobacterium.
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APPENDIX
SUPPLEMENTARY TABLES AND FIGURES

Table A1. Bacterial strains, plasmids and primers used in this study.
UMA, University of Massachusetts Amherst Culture Collection. In primers, start
codon and stop codon are underlined; restriction sites are indicated in lowercase.
Strains
Bifidobacterium strains
B. longum subsp. infantis UMA272
B. longum subsp. infantis UMA302
B. longum subsp. infantis UMA299
B. longum subsp. longum UMA306
B. longum subsp. suis UMA399
B. scardovii JCM12489
B. boum LMG10736

Genotype and relevant features

Source

Isolate from infant feces
Isolate from infant feces
Isolate from infant feces
Isolate from human feces
Isolate from infant rhesus macaque feces
Isolated from human blood
Isolated from bovine rumen

This study
This study
This study
This study
This study
JCM
JCM

E. coli strains
Rosetta (DE3)
NEB 5-alpha
Plasmids
pSMT3

F- ompT hsdSB,(rB- mB-) gal dcm (DE3) pRARE
(Cmr)
fhuA2 ∆(argF-lacZ)U169 phoA glnV44 Φ80Δ
(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1
hsdR17

pSMT-U

5.8-kb, E. coli expression vector, encoding an Nterminal, Ulp1-cleavable 6xHis-Sumo tag, Kanr
pSMT3 carrying the wild-type or mutant ureC

pDOJHR

8.5-kb, E. coli-Bifidobacterium shuttle vector, Cmr

pDOJ-U

pDOJHR carrying the wild-type ureC
pDOJHR carrying the cyK and metB from
UMA399

pDOJ-cysK-metB

This study
New England
Biolabs

[120]
This study
(Lee & O'Sullivan,
2006)
This study
This study

Primers
PSM-F
PSM-R
PD-F
PD-R
CYS-F
CYS-R

5’-gctaggatccATGAAGATTATTACGC-3’
5’-tcgtctcgagTCAGAACAGGAAGTAC-3’
5’-taacgaattcTGTGAGGTTCGAGC-3’
5’-gagcgaattCATTTCGTGACCGAA-3’
5’-TGAGgaattcCGTGGTTAACATGA-3’
5’-TAATgaattcGAGTCCGCCGATAA-3’

JCM, Japan Collection of the Microorganisms.
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This study
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Figure A1. Growth phenotype of mutant, UMA399, Mutant + pDOJHR, and
Mutant + pDOJ-U while growing in complex nitrogen.
Mutant + pDOJHR: mutant transferred with pDOJHR; Mutant + pDOJ-U: mutant
transferred with pDOJ-U. UMA399 is the wild-type strain. The continuous growth
curves display the optical density at 600 nm at each time point by mean ± SD
(standard deviation) from three individual biological replicates (n = 3).
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Figure A2. Growth phenotype of mutant, UMA399, Mutant + pDOJHR and
Mutant + pDOJ-U while growing in negative control medium.
Mutant + pDOJHR: mutant transferred with pDOJHR; Mutant + pDOJ-U: mutant
transferred with pDOJ-U. UMA399 is the wild-type strain. The continuous growth
curves display the optical density at 600 nm at each time point by mean ± SD
(standard deviation) from three individual biological replicates (n = 3).
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Figure A3. Predicted urease active site of UMA399 UreC
The Urease active site of UMA399 UreC. Ni2+ ions are shown in green; Amino acid
residues in correlation with Ni2+ are shown in red carbon atoms, labeled with 3-letter
code and number.
Figure A4. Construction of the UreC expression vector pSMT-U
The ureC fragment from wild-type and the mutant strain indicated in red was cloned in
between the BamHI and XhoI sites on the vector pSMT3, forming pSMT-U.
XhoI

BamHI

pSMT-U
7321 bp

INS ERT
FRAGMENT Replace

BamHI (5431)

Insert
BamHI (1)

XhoI (5683)

XhoI (1729)

XhoI
BamHI

BamHI

XhoI

ureC

1734 bp

pSMT3
5845 bp
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Figure A5. Construction of the UreC expression vector pDOJ-cysK-metB
The cystathionine beta-synthase and gamma-lyase indicated in red was cloned in
between the EcoRI sites on the vector pDOJHR, forming pDOJ-cysK-metB

EcoRI

EcoRI

pDOJ-cysK-metB
9662 bp

I NSE R T
FR A GME NT Replace

EcoRI (3157)

Insert
EcoRI (1)

EcoRI (4731)

EcoRI

EcoRI

EcoRI (2641)

EcoRI

uma399 cysteine genes with pro and term and cut sites
2646 bp

EcoRI

pDOJHR
8596 bp
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Figure A6. Growth phenotype of B. boum LMG10736 while growing in cysteine
as the sole nitrogen source.
The continuous growth curves display the optical density at 600 nm at each time point
by mean ± SD (standard deviation) from three individual biological replicates (n = 3).
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Figure A7. Growth phenotype of B. boum LMG10736 while growing in methionine
as the sole nitrogen source.
The continuous growth curves display the optical density at 600 nm at each time point
by mean ± SD (standard deviation) from three individual biological replicates (n = 3).
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Figure A8. Growth phenotype of B. boum LMG10736 while growing in glutamine
as the sole nitrogen source.
The continuous growth curves display the optical density at 600 nm at each time point
by mean ± SD (standard deviation) from three individual biological replicates (n = 3).
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